Financial StabilityCash runway is expected to fund operations into the second half of 2027, providing financial stability for ongoing projects.
Strategic FocusThe strategic pivot focuses resources on siRNA for autoimmune disorders, showing a clear direction for future developments.
Technological AdvancementsRecent data demonstrated the effectiveness of ctLNPs in targeting T-cells, highlighting the potential of their technology in treating autoimmune diseases.